» Articles » PMID: 16038758

The Use of Corticosteroid As Treatment in SARS Was Associated with Adverse Outcomes: a Retrospective Cohort Study

Overview
Journal J Infect
Date 2005 Jul 26
PMID 16038758
Citations 123
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To study the effect of corticosteroids in the treatment of severe acute respiratory syndrome (SARS).

Methods: A retrospective cohort of 78 consecutive adult SARS patients admitted to a regional hospital in Hong Kong between March and May 2003 was analysed to study the effectiveness of corticosteroid. They were categorized according to whether or not corticosteroid therapy was given, and compared in terms of demographic characteristics, comorbidities, peak lactate dehydrogenase (LDH) levels and clinical outcomes. Established adverse prognostic factors including old age, comorbidities and high LDH levels were used as covariates in multiple logistic regressions to adjust for their confounding effect on adverse outcomes.

Results: Among 78 patients, 66 patients (84.6%) received corticosteroid. The LDH level was similar in both groups. The corticosteroid group had more adverse outcomes (37.9% vs. 16.7%) despite younger age and less comorbidity. In multivariate analysis, corticosteroid treatment was associated with a 20.7-fold increase in risk of either ICU admission or mortality, independent of age and disease severity.

Conclusion: Despite more favourable baseline characteristics and similar peak LDH levels, SARS patients given corticosteroid had more adverse outcomes.

Citing Articles

Beneficial effect of sequential treatment with high-dose steroids and short-course oral glucocorticoids in patients with severe influenza virus-associated pneumonia.

Li W, Gao M, Hao Y, Chi H, Yu J Sci Rep. 2024; 14(1):25023.

PMID: 39443650 PMC: 11499680. DOI: 10.1038/s41598-024-76400-2.


The critical impacts of cytokine storms in respiratory disorders.

Riyaz Tramboo S, Elkhalifa A, Quibtiya S, Ali S, Shah N, Taifa S Heliyon. 2024; 10(9):e29769.

PMID: 38694122 PMC: 11058722. DOI: 10.1016/j.heliyon.2024.e29769.


Relationship between glucocorticoids and viral load during the Omicron wave in mainland China.

Bai G, Li Y, Liu Y, Wang X, Yu X, Ren L Virol J. 2023; 20(1):273.

PMID: 37993863 PMC: 10666395. DOI: 10.1186/s12985-023-02235-4.


Femoral head avascular necrosis in COVID-19 survivors: a systematic review.

Hassan A, Khalifa A Rheumatol Int. 2023; 43(9):1583-1595.

PMID: 37338665 PMC: 10348993. DOI: 10.1007/s00296-023-05373-8.


Dose-Response Meta-Analysis of Corticosteroid Effects in SARS Outbreak: A Model for Risk Stratification and Screening Strategy for Osteonecrosis of Femoral Head Post-Corticosteroid Therapy for COVID-19.

Muthu S, Jeyaraman M, Selvaraj P, Jeyaraman N, Potty A, Gupta A Life (Basel). 2023; 13(4).

PMID: 37109436 PMC: 10143798. DOI: 10.3390/life13040907.


References
1.
Avendano M, Derkach P, Swan S . Clinical course and management of SARS in health care workers in Toronto: a case series. CMAJ. 2003; 168(13):1649-60. PMC: 161610. View

2.
Choi K, Nin Chau T, Tsang O, Tso E, Chiu M, Tong W . Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med. 2003; 139(9):715-23. DOI: 10.7326/0003-4819-139-9-200311040-00005. View

3.
Wong G, Hui D . Severe acute respiratory syndrome (SARS): epidemiology, diagnosis and management. Thorax. 2003; 58(7):558-60. PMC: 1746727. DOI: 10.1136/thorax.58.7.558. View

4.
Sampathkumar P, Temesgen Z, Smith T, Thompson R . SARS: epidemiology, clinical presentation, management, and infection control measures. Mayo Clin Proc. 2003; 78(7):882-90. PMC: 7094524. DOI: 10.4065/78.7.882. View

5.
Ho J, Ooi G, Mok T, Chan J, Hung I, Lam B . High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003; 168(12):1449-56. DOI: 10.1164/rccm.200306-766OC. View